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Abstract
Purpose
This systematic review with network meta-analysis compared the efficacy and safety of cur-
rently licensed second-line treatments in patients with late stage non-small cell lung cancer
(NSCLC).
Methods
Randomised controlled trials (RCTs) of participants with advanced/metastatic NSCLC
receiving second/third line treatments were screened. We searched electronic databases
(MEDLINE; EMBASE; Web of Science) from January, 2000 to July, 2017.
Two reviewers screened bibliographic records, extracted data, and assessed risk of bias
of included studies. The outcomes were overall survival (OS), progression-free survival
(PFS), and drug-related grade 3–5 adverse-events (AEs). We pooled study-specific hazard
ratios (HR; for OS and PFS) and risk ratios (RR; for AEs) using conventional and network-
meta-analyses, and ranked interventions by the surface under the cumulative ranking
curve.
Findings
We included 11 RCTs (7,581 participants) comparing nine drugs. All drugs except for erloti-
nib significantly improved OS compared to docetaxel. Nivolumab was the highest ranking
drug followed by atezolizumab and pembrolizumab. There was no significant difference in
OS across these three drugs (HR = 0.98, 95% CI 0.79, 1.21 for nivolumab vs atezolizumab;
HR = 0.98, 95% CI 0.77, 1.25 for nivolumab vs pembrolizumab). For PFS, ramucirumab +
docetaxel and nivolumab were the drugs with the highest ranking. All interventions except
ramucirumab + docetaxel had a reduced risk for severe drug-related AEs vs. docetaxel. Of
the drugs with the highest ranking on AEs, nivolumab was significantly safer compared to
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Implications
Nivolumab, pembrolizumab and atezolizumab exhibited superior benefit/risk balance com-
pared to other licensed drugs used late stage NSCLC. Our results indicate that the use of
immunotherapies in people diagnosed with non-specific late stage NSCLC should be pro-
moted. The use of docetaxel may now be judged irrelevant as a comparator intervention for
approval of new drugs for second line treatment of NSCLC.
Study registration number
PROSPERO CRD42017065928.
Introduction
Lung cancer remains one of the most common cancers worldwide [1], with non-small cell
lung cancer (NSCLC) accounting for 85 to 90% of all forms of lung cancer.[2] Because NSCLC
is predominantly diagnosed at a late stage, most patients are not eligible for otherwise curative
surgery, and thus have poor prognoses. While many first-line chemotherapies are available for
patients with advanced/ metastatic NSCLC, second-line therapeutic options have been limited
to docetaxel.[3] The development of targeted therapies and immunotherapies promises to fill
some of the unmet need for the treatment of advanced/ metastatic NSCLC. In 2017, 13 agents
had a label indication for the treatment of advanced/ metastatic NSCLC in patients after failure
to respond to first-line chemotherapy. This includes three immune checkpoints (nivolumab,
pembrolizumab, and atezolizumab). Although the effectiveness and safety of these drugs have
been compared to those of docetaxel, they have not been compared to each other head-to-
head.
In this systematic review and network meta-analysis (NMA), we compared the clinical effi-
cacy and safety of the agents according to their licensed indication in patients with NSCLC
(free of anaplastic lymphoma kinase [ALK] positive and Epidermal growth factor receptor
[EGFR] positive expression) for whom first-line treatments failed.
Methods
We registered a protocol for this review in PROSPERO (CRD42017065928) (Study protocol in
S1 File; Prisma checklist in S2 File).
Eligibility criteria: Studies, participants, and interventions
We included randomised controlled trials (RCTs) of people with advanced or metastatic (IIIB
or IV) NSCLC of squamous, non-squamous, or mixed histology who experienced failure to
prior first-line chemotherapy. Study populations had to have negative or predominantly nega-
tive expressions of ALK and EGFR. Patients with ALK and/or EGFR positive expression were
ineligible, since they would be offered targeted therapies (e.g., erlotinib, gefitinib, osimertinib,
crizotinib, or ceretinib).[1]
The interventions of interest were the drugs with a European Medicines Agency (EMA) ()
label indication for the population described above as of June, 2017: Docetaxel (DOC),
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Pemetrexed (PEM), Ramucirumab plus docetaxel (RAM + DOC), Erlotinib (ERL), Nintedanib
plus docetaxel (NINTE + DOC), Afatinib (AFA), Nivolumab (NIVO), Pembrolizumab (PEM-
BRO), and Atezolizumab (ATEZO). The efficacy outcomes assessed were overall survival
(OS), progression-free survival (PFS), the proportion of patients reporting at least one drug-
related grade 3 to 5 adverse event (AE), and the proportion of patients discontinuing study
medication due to a drug-related AE.
Search strategy and study selection
English language studies were searched in databases (MEDLINE; EMBASE; Web of Science)
from January, 2000 to July, 2017 (Supplementary online material A in S3 File).
Reference lists of relevant studies were scanned to identify additional citations. We con-
sulted the EMA website to identify trials submitted by manufacturers in support of included
drugs and sought relevant conference abstracts via relevant web sites.
Three reviewers (X.A., A.T., & M.C.) independently screened all titles/abstracts and exam-
ined full-text publications of potentially relevant citations. Disagreements were discussed and
resolved through consensus. The study flow and reasons for exclusion at the full-text level
were documented in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) flow-chart. [4]
Review outcomes and data extraction
Two reviewers (X.A. & A.T.) independently extracted relevant data using an a priori defined
pre-piloted extraction sheet. Data extracted included study author, country, funding source,
sample size, patient characteristics (age, sex, diagnosis, data on tumour stage/histology), type,
mode, dose and duration of treatments, dropouts, efficacy/safety outcomes of interest. The
data extracted were cross-checked and any disagreements were resolved by discussion or
recourse to another reviewer (M.C.).
For each study, we ascertained the estimates of hazard ratio (HR) for OS and PFS and risk
ratios (RR) for drug-related grade 3 to 5 AEs, and discontinuation of study medication due to
drug-related AE with corresponding 95% confidence intervals (95% CI). We extracted the
HRs as reported in the primary studies. These were all derived from Cox regression stratified
according to strata specified for randomisation. HRs adjusted for variables additional to ran-
domisation strata were not included in the NMA. If time to progression (TTP) was reported,
but not PFS, we used the TTP HR as a proxy for PFS HR. We used “treatment-emergent AEs”
as a proxy for drug-related grade 3 to 5 events, if the latter was not reported.
When study results were available for different follow-ups, we extracted the outcomes from
the latest follow-up irrespective of the publication type. To address incomplete reporting of
outcomes, we used methods published by Tierney et al. [5] and by Guyot et al. [6]
Risk of bias assessment
Two reviewers independently assessed the risk of bias (RoB) (per outcome: OS and PFS) using
the Cochrane RoB tool (Details in Supplementary online material B in S3 File). [7]
Data synthesis and analysis
Study and population characteristics were summarised in text and evidence tables. Where pos-
sible, analyses were stratified by histologic subtypes (squamous and non-squamous) and
tumour stage. The analyses included patients with adenocarcinoma but not those with non-
squamous histology [8, 9], or where the licensed indication was only for adenocarcinoma [10]
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in the non-squamous analyses. The label indication for PEM specifies NSCLC “other than pre-
dominantly squamous histology,” hence PEM was excluded from squamous analyses. For
PEMBRO [9], we analysed data from the licenced 2mg/kg arm.
We used pairwise random-effects meta-analysis to pool the study-specific estimates with
95% CIs. The heterogeneity across trials was examined by visual inspection of forest plots and
I2 statistics (I2>50% indicating a substantial degree of heterogeneity). Sensitivity analyses were
planned to assess the robustness of effect estimates across two RoB domains: allocation con-
cealment and blinding of outcome assessors.
We assessed the transitivity assumption [11] by examining the distribution of the effect
modifiers across studies (age, sex, performance status, stage IIIB vs IV at inclusion, and num-
ber of prior lines) and the dosages of common comparators used as anchor(s). Where possible,
we planned to use a node-splitting test within each network with a loop to assess inconsistency
between direct and indirect evidence. [12]
We undertook random-effects network meta-analyses in the frequentist framework. Where
there were few studies for each contrast between two treatments, we used a fixed- effect model.
Summary league tables were generated for all comparisons. [13]
We generated the surface under the cumulative ranking curve (SUCRA) to rank each inter-
vention (i.e., probability of an intervention being superior in effectiveness or safety compared
to DOC). [13]
Clustered ranking plots for efficacy/safety outcomes were produced. [14] The threshold for
the statistical significance was chosen as a two-tailed alpha = 0.05. All statistical analyses were
performed using Stata1 version 14.2 (StataCorp, USA).
Results
Of 1,949 records identified and screened at title/abstract level, 94 were examined for full-text,
of which 46 records [8–10, 15–57] corresponding to 11 RCTs with a total of 7,581 participants
were included (Fig 1).
Among the 46 records, 31 [15–45] were supplementary sources of the main publications
and three [46, 52, 56] were conference abstracts presenting updated results from primary pub-
lications. [8–10, 47–51, 53–55, 57]
Characteristics of included studies
The mean age at inclusion in the eleven RCTs ranged from 57 to 66 years with a majority of
male participants. The sample size ranged from 219 [8] to 1314 [10] patients. All studies
included predominantly people with stage IV NSCLC and performance status 1. Only two
studies had histology-specific inclusion criteria. [47, 48]
The included RCTs compared nine different drugs (AFA, ATEZO, DOC, ERL, NINTE--
DOC, NIVO, PEMBRO, PEME, RAMU+DOC), majority of which were compared to DOC.
Six RCTs [10, 47, 48, 50, 51, 57] included only people receiving second-line treatment, while
four others [9, 49, 53, 54] included those receiving both second- and third-lines. In KEY-
NOTE-010 [9] (PEMBRO vs DOC) study, patients had tumours expressing PD-L1 with a1%
tumour proportion score (TPS) (consistent with the marketing authorisation of PEMBRO).
The characteristics of included studies are presented in Table 1.
Nine studies [8, 9, 47–49, 51, 53, 54, 57] were considered at high risk of bias for PFS and OS
(due to the lack of blinding of participants and personnel). The five RCTs [9, 47–49, 54] evalu-
ating immunotherapies were open-label and therefore were rated as high-risk on the domain
of performance bias.
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The only study at low RoB for all the domains was LUME-LUNG 1. [10] The majority of
studies were rated as high-risk on ‘other domains of bias’ due to being funded by industry
(Supplementary online material B in S3 File).
Fig 1. PRISMA flowchart for study selection.
https://doi.org/10.1371/journal.pone.0199575.g001
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There was no substantial imbalance in the distribution of the effect modifiers across studies
in the networks. The dosages and administration modes of the anchored treatments across tri-
als were consistent.
Efficacy outcomes (overall analysis regardless of histology groups)
The evidence formed a connected star-shaped network with only a single RCT for most of the
comparisons (Fig 2). [8, 9, 50] Four included RCTs were not presented in the network plot
because in these one of the evaluated interventions was restricted in its label indication to one
specific histology subgroup (i.e. the intervention is not licenced for NSCLC irrespective of the
patient’s tumour histology). [10, 51, 53, 57] These four RCTs were used in the analyses by his-
tological subgroup the results of which are reported in the subsequent sections.
There was no evidence suggesting that the transitivity assumption was violated in any of the
networks.
Fig 2. Network of studies comparing effectiveness (OS, PFS) and safety (grade 3–5 drug-related AE) outcomes in all-histology NSCLC.
https://doi.org/10.1371/journal.pone.0199575.g002
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The inconsistency test was not conducted as planned due to the absence of closed loops in
the network.
Overall survival. Four drugs (NIVO, ATEZO, PEMBRO, and RAMU+DOC) showed a
significant improvement on OS compared to DOC in head-to-head comparisons (Fig 3). Indi-
rect comparisons of drugs superior to DOC showed greater SUCRA values for the checkpoint
inhibitors NIVO (0.82), ATEZO (0.77), PEMBRO (0.77) than for RAMU+DOC (0.42)
(Table 2). There was no significant difference in OS across three highest ranking drugs
Fig 3. Pairwise meta-analyses, OS in all-histology NSCLC.
https://doi.org/10.1371/journal.pone.0199575.g003
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(HR = 0.98, 95% CI 0.79, 1.21 for NIVO vs ATEZO; HR = 0.98, 95% CI 0.77, 1.25 for NIVO vs
PEMBRO).
Progression-free survival. In head-to-head comparisons, only RAMU+DOC showed a
significant improvement in PFS compared to DOC (Supplementary online material C in S3
File). Only the RAMU+DOC vs ERLO and NIVO vs ERLO indirect comparisons reached sta-
tistical significance (Table 2). The SUCRA rankings suggested RAMU+DOC (0.84) as the best
intervention followed by NIVO (0.81), PEMBRO (0.57), ATEZO (0.45), DOC (0.31) and
ERLO (0.02) which ranked last.
Table 2. Network meta-analyses: PFS, OS, grade 3–5 AE in all-histology NSCLC.
OS comparisons (Findings are expressed as HR (95% CI), use of random-effects model.
Drug SUCRA Nivo Atezo Pembro Ramu+Doc Doc Erlo
Nivo 0.82 0.98
(0.79,1.21)
0.98
(0.77,1.25)
0.82
(0.67,1.00)
0.71
(0.61,0.82)
0.55
(0.37,0.82)
Atezo 0.77 1.00
(0.79,1.27)
0.84
(0.69,1.02)
0.72
(0.62,0.83)
0.56
(0.38,0.83)
Pembro 0.77 0.84
(0.67,1.05)
0.72
(0.60,0.87)
0.56
(0.37,0.85)
Ramu+Doc 0.42 0.86
(0.75,0.98)
0.67
(0.46,0.99)
Doc 0.18 0.78
(0.54,1.12)
Erlo 0.02
PFS comparisons (Findings expressed as HR (95% CI), use of random-effects model.
Drug SUCRA Ramu
+Doc
Nivo Pembro Atezo Doc Erlo
Ramu
+ Doc
0.84 0.98
(0.68,1.41)
0.86
(0.58,1.29)
0.80
(0.57,1.14)
0.76
(0.58,0.99)
0.55
(0.35,0.88)
Nivo 0.81 0.88
(0.60,1.29)
0.82
(0.59,1.13)
0.77
(0.61,0.99)
0.56
(0.36,0.88)
Pembro 0.57 0.93
(0.64,1.35)
0.88
(0.65,1.18)
0.64
(0.39,1.03)
Atezo 0.45 0.95
(0.76,1.18)
0.69
(0.44,1.06)
Doc 0.31 0.72
(0.50,1.06)
Erlo 0.02
Grade 3–5 AE comparisons (Findings are expressed as RR (95% CI), use of random-effects model.
Drug SUCRA Nivo Atezo Pembro Erlo Doc Ramu+Doc
Nivo 1 0.55
(0.38,0.79)
0.52
(0.34,0.81)
0.46
(0.29,0.72)
0.18
(0.14,0.25)
0.17
(0.12,0.23)
Atezo 0.68 0.95
(0.66,1.38)
0.83
(0.55,1.23)
0.34
(0.28,0.41)
0.31
(0.25,0.38)
Pembro 0.63 0.87
(0.54,1.39)
0.35
(0.26,0.48)
0.32
(0.23,0.44)
Erlo 0.49 0.41
(0.29,0.58)
0.37
(0.26,0.53)
Doc 0.2 0.91
(0.85,0.97)
Ramu+Doc 0
Note: The table must be read as the drug on the column against the drug on the row. For example the PFS HR of
ramucirumab+docetaxel against nivolumab is 0.98 (95%CI 0.68, 1.41).
https://doi.org/10.1371/journal.pone.0199575.t002
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Drug-related grade 3–5 adverse events. Direct comparisons (Supplementary online
material D in S3 File) showed significantly reduced risk of drug-related grade 3–5 AE with
NIVO, ATEZO, PEMBRO, and ERLO compared to DOC alone. The same drugs were associ-
ated with reduced risk of these AEs compared to RAMU+DOC in indirect comparisons
(Table 2). The SUCRA values for the checkpoint inhibitors were higher (range: 0.63–1.00)
than for ERLO (0.49). Of the three highest ranking drugs (NIVO, ATEZO, PEMBRO), the
safety profile of NIVO was significantly better than that of ATEZO (RR = 0.55, 95% CI 0.38,
0.79) and PEMBRO (0.52, 95% CI 0.34, 0.81).
Discontinuation due to drug-related AE. No NMA could be conducted for this outcome,
because unlike for the previous outcome (Supplementary online material E in S3 File) the RR
estimates from direct comparisons were not stable across different points of study follow-up
(Supplementary online material F in S3 File).
Overall results (cluster rank analysis). Overall, NIVO, ATEZO and PEMBRO exhibited
dominance in efficacy and safety over alternative therapies. According to the cluster rank
analysis, NIVO was the drug with both the highest probability of being the most effective
(overall survival) and the safest (drug-related grade 3–5 AEs) followed by ATEZO and PEM-
BRO (Fig 4).
Efficacy outcomes by histology subgroups
The NMA for safety outcomes could not be performed due to sparse data.
Squamous histology. Head-to-head comparisons for OS and PFS are reported in Supple-
mentary online materials G and H (both in S3 File), respectively. The studies formed con-
nected, but sparse networks for OS and PFS, because not all studies reported these outcomes
(Supplementary online material I in S3 File).
For OS, the SUCRA rankings suggested that NIVO (0.89) was the best intervention fol-
lowed by ATEZO (0.72), PEMBRO (0.65), RAMU+DOC (0.42), AFA (0.46), DOC (0.20), with
ERLO (0.16) ranking the last (Supplementary online material J in S3 File). Indirect comparison
estimates between checkpoint drugs (PEMBRO, ATEZO, and NIVO) vs. each other or vs.
RAM + DOC or AFA were not significantly different. For PFS, the SUCRA rankings suggested
that NIVO (0.95) was the best intervention followed by RAMU+DOC (0.76), PEMBRO (0.61),
DOC (0.41), and AFA (0.25), with ERLO (0.02) ranking the last (Supplementary online mate-
rial K in S3 File).
Non-squamous histology. Direct comparison estimates for OS and PFS are reported in
Supplementary online materials L and M, respectively with corresponding network plots in
Supplementary online material N (in S3 File). Based on the SUCRA rankings for OS (Supple-
mentary online material O in S3 File), checkpoint inhibitors (PEMBRO, ATEZO, and NIVO)
were the best interventions (0.94, 0.75, and 0.67, respectively) followed by PEM (0.59), NINTE
+ DOC (0.46), RAMU+DOC (0.46), and DOC (0.15), with ERLO (0.0) ranking the last.
Among the four drugs with the highest rankings on OS, no significant difference was
observed.
For PFS, the network plot included one closed loop allowing a mixed treatment comparison
between DOC, ERLO, and PEME (Supplementary online material N2 in S3 File). There was
no evidence of inconsistency for the mixed treatment comparison (DOC, ERLO, PEME com-
parisons) within this loop (p = 0.07). The SUCRA rankings from the NMA suggested that
RAMU+DOC (0.85) and NINTE+DOC (0.83) were the best interventions followed by PEM-
BRO (0.58) and NIVO (0.49), PEME (0.49), and DOC (0.16), with ERLO (0.10) ranking the
last (Supplementary online material P in S3 File). Among the four drugs with the highest rank-
ings on PFS, no significant difference was observed.
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Discussion
Overall, the evidence in this review indicated that the checkpoint inhibitors (NIVO, ATEZO,
and PEMBRO) were superior in improving OS compared to non-immunotherapies irrespec-
tive of population histology (mixed, squamous or non-squamous) in people with advanced or
metastatic NSCLC after failure to prior chemotherapy.
For PFS, the checkpoint inhibitors performed worse than RAM +DOC (in mixed and non-
squamous groups) and NINTE + DOC (in non-squamous groups) but were superior to other
interventions (AFA, ERLO, DOC +PEME + ERLO, PEME +DOC).
Indirect comparisons showed significantly reduced risks of drug-related grade 3–5 AEs
with checkpoint inhibitors (NIVO, ATEZO, and PEMBRO) compared to RAMU+DOC.
Taken together with OS results, this evidence suggested that the three immunotherapies were
superior to other treatments (AFA, ERLO, PEME, DOC).
Fig 4. Clustered ranking plot on effectiveness (OS) and safety (grade 3–5 drug-related AE) both expressed as SUCRAS. Note: Y and X axes represent the
cumulative ranking curve (SUCRA) to rank each intervention (i.e., probability between 0 to 1 of an intervention being superior in effectiveness or in safety
compared to DOC); the plot guides a reader with respect to the trade-off between safety (measured drug-related grade 3–5 AE) and effectiveness (measures as
OS) across the interventions: interventions in the right upper corner tend to be safer (higher SUCRA for AEs) and more effective (SUCRAs for OS) than those in
the left lower corner of the plot (with lower SUCRAs on both factors). Thus, the Fig 3 supports a superior efficacy and safety for NIVO, ATEZO, and PEMBRO
as opposed to DOC or ERLO. Also although NIVO compared to ATEZO and PEMBRO had similar effectiveness it appeared safer than the latter two.
https://doi.org/10.1371/journal.pone.0199575.g004
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The occurrence of drug-related AE is a time-varying outcome so that intervention compari-
sons are best examined using similar periods of exposure/follow-up per patient. In included
studies, safety outcomes were reported at different points of follow-up.
Results based on indirect comparisons suggested a significantly reduced risk of drug-related
grade 3–5 AEs with NIVO vs. ATEZO or PEMBRO (through DOC as the common compara-
tor). One explanation could be the non-uniform occurrence rate of these events in the DOC
arms (range: 35.9% [52] to 58.1% [46]) even though the same licenced dose regimen was used
and duration of DOC treatment was comparable across the studies. Baseline characteristics of
included patients do not suggest a particular reason explaining these differences. The inci-
dence of drug-related grade 3–5 AEs across immunotherapies arms also showed slight differ-
ences between the three immunotherapies (range: 7.6% for NIVO [48] to 14.8% for ATEZO
[54]). Owing to the above-mentioned discrepancies and the limited number of trials for each
comparison, the observed more favourable safety profile of NIVO should be viewed with
caution.
Peng et al. [58] have previously reported similar results regarding the better safety profile of
NIVO vs PEMBRO.
In this work focusing on wild-type NSCLC (ALK and EGFR expression predominantly or
100% negative), ERLO was included although the summary of product characteristics for this
drug indicates that “no survival benefit or other clinically relevant effects of the treatment have
been demonstrated in patients with EGFR negative tumours”. However, we included ERLO in
our review, because we considered that the label indication does still theoretically include peo-
ple with EGFR—expression.
In patients with squamous histology, NIVO and ATEZO were the only drugs significantly
improving OS compared to DOC. Effectiveness of PEMBRO vs DOC was of similar as that of
ATEZO vs DOC but the former was not statistically significant, one explanation for which
could be lower statistical power in KEYNOTE-010 to show an OS benefit per histology. The
higher ranking of NIVO compared to ATEZO and PEMBRO observed for OS could be
explained by a lower rate of OS in the DOC arm in CHECKMATE-017 [48] compared to that
in OAK [54] or in REVEL. [26] The low number of studies per comparison limited the inter-
pretation of these findings. Although this subgroup analysis suggested the immunotherapies as
the most effective for OS, there was little evidence showing one of the three drugs of this class
being superior to another.
The meta-analyses in patients with non-squamous histology showed significantly improved
OS with all the drugs except for ERLO compared to DOC. None of the indirect comparisons
across PEMBRO, ATEZO, NIVO, PEME, NINTE+DOC and RAMU+DOC showed a signifi-
cant improvement in OS. We were unable to meaningfully compare drugs on safety outcomes
in the histology-specific subgroups of patients.
A recently published systematic review with NMA synthesised 102 RCTs to assess the effi-
cacy and safety of 61 second-line treatments for patients with NSCLC regardless whether or
not drugs (or drug combinations) were licensed or commercialised in this population. [59]
Although the review authors provided a comprehensive evidence synthesis, their findings may
have limited applicability to routine clinical practice. In contrast, the focus on licensed indica-
tions and dose regimens renders our review clinically more relevant.
Our work has several limitations. Although we used a systematic search approach we may
have missed some unpublished relevant studies with null findings, so the potential for publica-
tion bias cannot be excluded. Because of the scarcity of evidence, we could not assess if RoB
affected the NMA results due to either the lack of blinding or to industry sponsorship that
potentially might influence some findings. Different definitions of safety outcomes and their
reporting at different follow-ups may have affected the validity of drug comparisons. A further
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limitation is that in our NMA we used Cox regression model-based HR estimates that were
stratified according to characteristics specified for randomisations, the use of which was not
entirely consistent across the analysed studies.
In general, the differences in potential effect modifiers across studies were not substantial to
violate the transitivity assumption.
The applicability of this review results may be limited owing to a changing landscape for
the first-line treatment because immunotherapies are becoming standard treatments in this
setting. This is particularly the case for PEMBRO which demonstrated improved survival out-
comes compared to platinum-based chemotherapy in people with PD-L1 expression50%.
[60] Should PEMBRO become a standard care at first line, one can assume that people with
PD-L1 expression50% receiving PEMBRO at first-line and progressing will not receive sub-
sequent lines of other immunotherapies. Therefore, our findings may not be applicable for
people with PD-L1 expression50% (around 30% of NSCLC [60]).
Conclusions
In this review, we advanced the existing knowledge by comparing drugs approved in people
with non-specific late-stage NSCLC. Our results indicate that the use of immunotherapies in
people diagnosed with non-specific late stage NSCLC should be promoted. Amongst our
included studies, more than 3,500 patients received licensed dosing of DOC, which proved rel-
atively unsuccessful on both survival and safety. The use of DOC may now be judged irrelevant
as a comparator intervention for approval of new drugs for second line treatment of NSCLC.
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